FRANKLIN LAKES, N.J., March 14, 2012 /PRNewswire/ -- The final results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) study will be presented at the American College of Cardiology's 61st Annual Scientific Session & Expo being held March 24-27, 2012, in Chicago, IL. The AKROBATS study is a collaborative effort between the Medco Research Institute™, a subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) and Quest Diagnostics (NYSE: DGX), the world's leading diagnostic testing company. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) Presentation Details Session Number: 1258 Session Type: ACC Moderated Poster Contributions Session Start/End Time: Monday, Mar 26, 2012, 9:30 AM -10:30 AM Location: McCormick Place South, Hall A Presentation Number: 1258-376 Abstract Title: Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Presenter: Scott L. Charland, Pharm.D., Medco Research Institute About AKROBATS AKROBATS is prospective, nonrandomized intervention trial of the effect of KIF6 testing results reported directly to the patient on statin adherence and persistence over six months. All eligible intervention and control patients were greater than or equal to 18 years old, new to statin therapy (none 6 months prior), and from the same sponsored plans (which had granted permission for their members to participate in the study). Genetic testing for a common single nucleotide polymorphism (rs20455) resulting in an arginine to tryptophan substitution at position 719 (Trp719Arg) in the kinesin-like protein 6 gene ( KIF6) was conducted and written results returned to the patient within 30 days of initiating statin therapy, and before the first statin prescription refill. Tested patients were matched to concurrent, non-tested control patients on age, gender, statin prescription distribution channel, and the number of chronic medications at time of statin initiation. The primary endpoint was statin adherence (proportion of days covered; PDC) at six months. Secondary end points included achievement of adherence (PDC greater than or equal to 0.80) and persistence to statin therapy at six months. AKROBATS is registered on www.clinicaltrials.gov (NCT01068834). About Medco Research Institute Medco Research Institute® is an evidence-based research organization focused solely on novel research, analytics and new discoveries that close the gap between scientific discovery and medical practice for improved patient outcomes and lower overall healthcare costs. More information about the Medco Research Institute's peer-reviewed research can be found at www.medcoresearch.com.